Evogene Ltd. (EVGN) is a leading biotechnology company leveraging computational predictive biology (CPB) to redesign the life-science product development process. Incorporated in 2002 and based in Rehovot, Israel, Evogene has developed a robust platform that accelerates the discovery and development of products in multiple life-science based industries such as human health, agriculture, and industrial applications. The company is publicly traded on the NASDAQ and Tel Aviv Stock Exchange.
Evogene takes a systematic approach to biological research, leaning heavily on big data analysis and advanced algorithmic procedures. Its artificial intelligence subsystem extracts the knowledge from vast amounts of data, and the combinatorial biology subsystem uses it to predict the potential impacts of specific genetic modifications. This innovative methodology expedites the discovery process, reducing cost and timelines considerably.
Evogene has a broad product pipeline and a diverse portfolio of subsidiaries and strategic collaborations. Subsidiaries include: Biomica Ltd., a microbiome-based company focused on human health; Lavie Bio Ltd., an agricultural biologicals company; Canonic Ltd., a company developing medical cannabis products; and AgPlenus Ltd., which designs effective and sustainable agrochemical products.
The company's subsidiary, Biomica, has announced preclinical results demonstrating potential of its live bacterial product (LBP) to treat inflammatory bowel disease, which has resulted in a significant and positive impact on the parent company's stock.
Evogene's significant partnerships include agreements with multinational corporations like Bayer, DuPont Pioneer now Corteva, and BASF, further demonstrating the company's global recognition and influence in the industry. Due to its scientific innovation and strong commercial collaborations, Evogene is poised to make a significant impact in its respective markets.
In the current era of technologically driven biotechnology, Evogene possesses significant competitive advantages in the development of products for improving the quality of human life. By harnessing the power of computational predictive biology, Evogene is helping to create a healthier, more sustainable world. Overall, Evogene Ltd. (EVGN) presents an appealing proposition for investors interested in biotechnology and artificial intelligence-driven healthcare solutions.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Evogene Ltd. (EVGN) has announced acute graft-versus-host disease (aGVHD) as the target for its AI-driven drug discovery program, aiming to develop a first-in-class small-molecule therapy. The program will leverage Evogene's ChemPass AI platform and expert collaborations to address the significant unmet medical need in treating severe, steroid-refractory aGVHD, a potentially life-threatening complication of stem cell transplantation. The company aims to target a specific overactive signaling pathway responsible for inflammation in these patients.
Evogene Ltd. is focusing its internal drug discovery efforts on acute graft-versus-host disease (aGVHD), particularly for steroid-refractory patients, utilizing its ChemPass AI platform. The company has identified novel small-molecule candidates with potent activity and favorable profiles. The program is guided by leading experts Dr. Corey Cutler and Prof. Dr. Robert Zeiser, aiming to address a significant unmet medical need in a multi-billion-dollar market.